Pasireotide: First Approved Peptide Drug for Cushing's Disease Targets Pituitary Tumor Cells
Pasireotide, a somatostatin analog peptide, normalizes cortisol in up to 28% of Cushing's disease patients as monotherapy and up to 50% when combined with cabergoline.
Quick Facts
What This Study Found
Pasireotide, a multi-receptor somatostatin analog peptide with high affinity for SST receptor 5, normalized urinary free cortisol levels in up to 28% of patients with Cushing's disease at doses of 600-1,200 μg twice daily after 3 months. Combining pasireotide with cabergoline increased the normalization rate to 50%, and adding ketoconazole achieved biochemical control in most patients. Treatment improved blood pressure, weight, lipid profile, and quality of life. Hyperglycemia is the main side effect, caused by pasireotide's suppression of insulin and GLP-1 secretion.
Key Numbers
600-1,200 μg twice daily · 28% cortisol normalization as monotherapy · 50% normalization with cabergoline combo · most patients controlled with triple therapy · FDA and EMA approved
How They Did This
This is a clinical review summarizing the pharmacology, clinical trial results, efficacy data, adverse effects, and practical management considerations for pasireotide use in adult Cushing's disease. It covers both monotherapy and combination therapy approaches.
Why This Research Matters
Cushing's disease is a serious condition caused by excess cortisol from a pituitary tumor. Before pasireotide, there was no FDA-approved medical therapy specifically targeting the pituitary tumor cells. Pasireotide represents a milestone as the first peptide drug approved for this indication, working by targeting SST receptor 5 — the predominant somatostatin receptor in corticotroph tumors that remains functional even when cortisol levels are high.
The Bigger Picture
Pasireotide exemplifies how understanding receptor pharmacology can lead to targeted peptide therapeutics. While older somatostatin analogs like octreotide targeted SST receptor 2 (which is downregulated by high cortisol), pasireotide was designed to target SST receptor 5, which remains active. This receptor-specific approach represents a broader trend in peptide drug design — creating analogs with tailored receptor binding profiles for specific disease applications.
What This Study Doesn't Tell Us
As a review, no new data are presented. The normalization rate of 28% as monotherapy means most patients don't achieve full biochemical control with pasireotide alone. Hyperglycemia is a significant and common side effect that complicates management. Long-term efficacy and safety data beyond the initial clinical trials were limited at the time of publication.
Questions This Raises
- ?Can newer formulations of pasireotide (long-acting monthly injections) improve patient compliance and outcomes?
- ?Could combining pasireotide with GLP-1 receptor agonists address both the cortisol excess and the hyperglycemia side effect simultaneously?
- ?What are the long-term outcomes of pasireotide therapy beyond the initial clinical trial follow-up periods?
Trust & Context
- Key Stat:
- 28% cortisol normalization (monotherapy) As the first FDA-approved medical therapy for Cushing's disease, pasireotide normalizes cortisol in about 1 in 4 patients alone, increasing to 50% with cabergoline and higher with triple therapy.
- Evidence Grade:
- This review summarizes data from phase II and III clinical trials that led to FDA and EMA approval of pasireotide for Cushing's disease. The regulatory approval indicates a high level of clinical evidence, though the review itself is a narrative synthesis.
- Study Age:
- Published in 2015, shortly after pasireotide's regulatory approval. Since then, a long-acting monthly formulation (pasireotide LAR) has been developed, and more clinical experience has accumulated.
- Original Title:
- Clinical use of pasireotide for Cushing's disease in adults.
- Published In:
- Therapeutics and clinical risk management, 11, 425-34 (2015)
- Authors:
- Ceccato, Filippo, Scaroni, Carla, Boscaro, Marco
- Database ID:
- RPEP-02598
Evidence Hierarchy
Frequently Asked Questions
How does pasireotide differ from older somatostatin analogs like octreotide?
Pasireotide binds to somatostatin receptor 5, which is the main receptor type found on the pituitary tumor cells that cause Cushing's disease. Older analogs like octreotide primarily target receptor 2, which gets turned off by high cortisol levels. Pasireotide's unique binding profile makes it effective where other somatostatin analogs fail.
Why does pasireotide cause high blood sugar?
Pasireotide suppresses the secretion of insulin from the pancreas and reduces the production of GLP-1, a gut peptide that normally helps control blood sugar after meals. This double hit on blood sugar regulation means patients need careful monitoring and often require diabetes medications, starting with metformin and potentially adding GLP-1 receptor agonists or insulin.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02598APA
Ceccato, Filippo; Scaroni, Carla; Boscaro, Marco. (2015). Clinical use of pasireotide for Cushing's disease in adults.. Therapeutics and clinical risk management, 11, 425-34. https://doi.org/10.2147/TCRM.S37314
MLA
Ceccato, Filippo, et al. "Clinical use of pasireotide for Cushing's disease in adults.." Therapeutics and clinical risk management, 2015. https://doi.org/10.2147/TCRM.S37314
RethinkPeptides
RethinkPeptides Research Database. "Clinical use of pasireotide for Cushing's disease in adults." RPEP-02598. Retrieved from https://rethinkpeptides.com/research/ceccato-2015-clinical-use-of-pasireotide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.